Precursor Lesions of Prostate Cancer

REFERENCES

• Nelson W G, De Marzo A M, Isaacs W B. Prostate cancer. N Engl J Med 2003; 349: 366–381
   PubMed Web of Science ®Google Scholar
• Papatsoris A G, Papavassiliou A G. Prostate cancer: horizons in the development of novel anti-cancer strategies. Curr Med Chem Anticancer Agents 2001; 1: 47–70
   PubMedGoogle Scholar
• Papatsoris A G, Karamouzis M V, Papavassiliou A G. Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC). Curr Med Chem 2005; 12: 277–296
   PubMed Web of Science ®Google Scholar
• Vis A N, Van Der Kwast T H. Prostatic intraepithelial neoplasia and putative precursor lesions of prostate cancer: a clinical perspective. BJU Int 2001; 88: 147–157
   PubMedGoogle Scholar
• Orteil H. Involutionary changes in prostate and female breast cancer in relation to cancer development. Can Med Assoc J 1926; 16: 237
   PubMedGoogle Scholar
• McNeal J E. Morphogenesis of prostatic carcinoma. Cancer 1965; 18: 1659–1666
   PubMed Web of Science ®Google Scholar
• McNeal J E, Bostwick D G. Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 1986; 17: 64–71
   PubMed Web of Science ®Google Scholar
• Bostwick D G, Brawer M K. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 1987; 59: 788–794
   PubMed Web of Science ®Google Scholar
• Bostwick D G. Prostatic intraepithelial neoplasia (PIN). Urology 1989; 34: S16–S22, Suppl 6
   PubMedGoogle Scholar
• Shah R B, Kunju L P, Shen R, LeBlanc M, Zhou M, Rubin M A. Usefulness of basal cell cocktail (34betaE12+p63) in the diagnosis of atypical prostate glandular proliferations. Am J Clin Pathol 2004; 122: 517–523
   PubMedGoogle Scholar
• Billis A. Prostatic atrophy: an autopsy study of a histologic mimic of adenocarcinoma. Mol Pathol 1998; 11: 47–54
   Google Scholar
• Amin M B, Tamboli P, Varma M, Srigley J R. Postatrophic hyperplasia of the prostate gland: a detailed analysis of its morphology in needle biopsy specimens. Am J Surg Pathol 1999; 23: 925–931
   PubMedGoogle Scholar
• Franks L M. Atrophy and hyperplasia in the prostate proper. J Pathol Bacteriol 1954; 68: 617–621
   PubMedGoogle Scholar
• De Marzo A M, Marchi V L, Epstein J I, Nelson W G. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999; 155: 1985–1992
   PubMed Web of Science ®Google Scholar
• Bostwick D G. Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Cancer 1996; 78: 330–336
   PubMedGoogle Scholar
• Grignon D J, Sakr W A. Atypical adenomatous hyperplasia of the prostate: a critical review. Eur Urol 1996; 30: 206–211
   PubMedGoogle Scholar
• Cheville J C, Bostwick D G. Postatrophic hyperplasia of the prostate. A histologic mimic of prostate adenocarcinoma. Am J Surg Pathol 1995; 19: 1068–1076
   PubMedGoogle Scholar
• Anton R C, Kattan M W, Chakraborty S, Wheeler T M. Postatrophic hyperplasia of the prostate: lack of association with prostate cancer. Am J Surg Pathol 1999; 23: 932–936
   PubMedGoogle Scholar
• Gaudin P B, Epstein J I. Adenosis of the prostate. Histologic features in transurethral resection specimens. Am J Surg Pathol 1994; 18: 863–870
   PubMedGoogle Scholar
• Gaudin P B, Epstein J I. Adenosis of the prostate Histological features in needle biopsy specimens. Am J Surg Pathol 1995; 19: 737–747
   PubMed Web of Science ®Google Scholar
• Bostwick D G, Qian J. Atypical adenomatous hyperplasia of the prostate. Relationship with carcinoma in 217 whole-mount radical prostatectomies. Am J Surg Pathol 1995; 19: 506–518
   PubMedGoogle Scholar
• Cheng L, Shan A, Cheville J C, Qian J, Bostwick D G. Atypical adenomatous hyperplasia of the prostate: a premalignant lesion?. Cancer Res 1998; 58: 389–391
   PubMed Web of Science ®Google Scholar
• Bostwick D G, Dousa M K, Crawford B G, Wollan P C. Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Surg Pathol 1994; 18: 1240–1246
   PubMed Web of Science ®Google Scholar
• Vis A N, Hoedemaeker R F, Roobol M, Schroder F H, van der Kwast T H. The predictive value for prostate cancer of lesions that raise suspicion of concomitant carcinoma: an evaluation from a randomized population-based study of screening for prostate cancer. Cancer 2001; 92: 524–534
   PubMed Web of Science ®Google Scholar
• Fadare O, Wang S, Mariappan M R. Practice patterns of clinicians following isolated diagnoses of atypical small acinar proliferation on prostate biopsy specimens. Arch Pathol Lab Med 2004; 128: 557–560
   PubMed Web of Science ®Google Scholar
• Iczkowski K A, Chen H M, Yang X J, Beach R A. Prostate cancer diagnosed after initial biopsy with atypical small acinar proliferation suspicious for malignancy is similar to cancer found on initial biopsy. Urology 2002; 60: 851–854
   PubMed Web of Science ®Google Scholar
• Iczkowski K A, MacLennan G T, Bostwick D G. Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies: clinical significance in 33 cases. Am J Surg Pathol 1997; 21: 1489–1495
   PubMed Web of Science ®Google Scholar
• Iczkowski K A, Bostwick D G. Criteria for biopsy diagnosis of minimal volume prostatic adenocarcinoma: analytic comparison with nondiagnostic but suspicious atypical small acinar proliferation. Arch Pathol Lab Med 2000; 124: 98–107
   PubMed Web of Science ®Google Scholar
• Iczkowski K A, Bassler T J, Schwob V S, Bassler I C, Kunnel B S, Orozco R E, Bostwick D G. Diagnosis of “suspicious for malignancy” in prostate biopsies: predictive value for cancer. Urology 1998; 51: 749–758
   PubMed Web of Science ®Google Scholar
• Scattoni V, Roscigno M, Freschi M, Deho F, Raber M, Briganti A, Fantini G, Nava L, Montorsi F, Rigatti P. Atypical small acinar proliferation (ASAP) on extended prostatic biopsies: predictive factors of cancer detection on repeat biopsies. Arch Ital Urol Androl 2005; 77: 31–36
   PubMedGoogle Scholar
• Helpap B, Kollermann J, Oehler U. Limiting the diagnosis of atypical small glandular proliferations in needle biopsies of the prostate by the use of immunohistochemistry. J Pathol 2001; 193: 350–353
   PubMed Web of Science ®Google Scholar
• Hellpap B, Kollermann J. Atypical acinar proliferation of the prostate. Pathol Res Pract 1999; 195: 795–799
   PubMedGoogle Scholar
• Moore C K, Karikehalli S, Nazeer T, Fisher H AG, Kaufman R P, Jr., Mian B M. Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation in the contemporary era. J Urol 2005; 173: 70–72
   PubMed Web of Science ®Google Scholar
• Brausi M, Castagnetti G, Dotti A, De Luca G, Olmi R, Cesinaro A M. Immediate radical prostatectomy in patients with atypical small acinar proliferation. Over treatment?. J Urol 2004; 172: 906–908
   PubMed Web of Science ®Google Scholar
• Sakr W A, Haas G P, Cassin B J, Pontes J E, Crissman J D. Frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993; 150: 379–385
   PubMed Web of Science ®Google Scholar
• Qian J, Wollan P, Bostwick D G. The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. Hum Pathol 1997; 28: 143–148
   PubMedGoogle Scholar
• Steiner M S. High-grade prostatic intraepithelial neoplasia and prostate cancer risk reduction. World J Urol 2003; 21: 15–20
   PubMed Web of Science ®Google Scholar
• Bostwick D G, Qian J, Frankel K. The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies. J Urol 1995; 154: 1791–1794
   PubMedGoogle Scholar
• Epstein J I. Pathology of prostatic neoplasia. Campell's Urology, 8th Ed., P C Walsh, A B Retik, E D Vaughan, A J Wein. Saunders, Philadelphia 2002; 3025–3037
   Google Scholar
• Sakr W A, Grignon D J, Haas G P, Schomer K L, Heilbrun L K, Cassin B J, Powell J, Montie J A, Pontes J E, Crissman J D. Epidemiology of high grade prostatic intraepithelial neoplasia. Pathol Res Pract 1995; 191: 838–841
   PubMedGoogle Scholar
• Epstein J I, Grignon D J, Humphrey P A, McNeal J E, Sesterhenn I A, Troncoso P, Wheeler T M. Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasia. Am J Surg Pathol 1995; 19: 873–886
   PubMed Web of Science ®Google Scholar
• Sakr W A, Grignon D J, Haas G P, Heilbrur L K, Pontes J E, Crissman J D. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996; 30: 138–144
   PubMed Web of Science ®Google Scholar
• Myers R B, Grizzle W E. Biomarker expression in prostatic intraepithelial neoplasia. Eur Urol 1996; 30: 153–166
   PubMed Web of Science ®Google Scholar
• Boag A H, Young I D. Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in situ hybridization. Am J Pathol 1994; 144: 585–591
   PubMedGoogle Scholar
• Swinnen J V, Roskams T, Joniau S, Van Poppel H, Oyen R, Heyns W, Verhoeven G. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 2002; 98: 19–22
   PubMed Web of Science ®Google Scholar
• Zeng L, Kyprianou N. Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention. Prostate Cancer Prostatic Dis 2005; 8: 7–13
   PubMed Web of Science ®Google Scholar
• Joniau S, Goeman L, Pennings J, Van Poppel H. Prostatic intraepithelial neoplasia (PIN): importance and clinical management. Eur Urol 2005; 48: 379–385
   PubMedGoogle Scholar
• Qian J, Bostwick D G, Takahashi S, Borell T J, Herath J F, Lieber M M, Jenkins R B. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 1995; 55: 5408–5414
   PubMed Web of Science ®Google Scholar
• Haggman M J, Macoska J A, Wojno K J, Oesterling J E. The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. J Urol 1997; 158: 12–22
   PubMed Web of Science ®Google Scholar
• Bostwick D G. Prostatic intraepithelial neoplasia is a risk factor for cancer. Semin Urol Oncol 1999; 17: 187–198
   PubMedGoogle Scholar
• Bostwick D G, Shan A, Qian J, Darson M, Maihle N J, Jenkins R B, Cheng L. Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostatic carcinoma. Cancer 1998; 83: 1995–2002
   PubMed Web of Science ®Google Scholar
• Bonkhoff H. Role of the basal cells in premalignant changes of the human prostate: a stem cell concept for the development of prostate cancer. Eur Urol 1996; 30: 201–205
   PubMed Web of Science ®Google Scholar
• Bostwick D G, Pacelli A, Lopez-Beltran A. Molecular biology of prostatic intraepithelial neoplasia. Prostate 1996; 29: 117–134
   PubMed Web of Science ®Google Scholar
• Sakr W A, Brawer M K, Moul J W, Donohue R, Schulman C G, Sakr D. Pathology and bio markers of prostate cancer. Prostate Cancer Prostatic Dis 1999; 2: S7–S14, (Supp1)
   PubMedGoogle Scholar
• Baretton G B, Vogt T, Blasenbreu S, Lohrs U. Comparison of DNA ploidy in prostatic intraepithelial neoplasia and invasive carcinoma of the prostate: an image cytometric study. Hum Pathol 1994; 25: 506–513
   PubMed Web of Science ®Google Scholar
• Baltaci S, Orhan D, Ozer G, Tolunay O, Gogous O. Bcl-2 proto-oncogene expression in low-and high-grade prostatic intraepithelial neoplasia. BJU Int 2000; 85: 155–159
   PubMed Web of Science ®Google Scholar
• Montironi R, Galluzzi C M, Diamanti L, Taborro R, Scarpelli M, Pisani E. Prostatic intra-epithelial neoplasia. Qualitative and quantitative analyses of the blood capillary architecture on thin tissue sections. Pathol Res Pract 1993; 189: 542–548
   PubMed Web of Science ®Google Scholar
• Newling D W. PIN I-II: when should we interfere?. Eur Urol 1999; 35: 504–507
   PubMed Web of Science ®Google Scholar
• Bostwick D G. Prostatic intraepithelial neoplasia. Curr Urol Rep 2000; 1: 65–70
   PubMedGoogle Scholar
• Keetch D W, Humphrey P, Stahl D, Smith D S, Catalona W J. Morphometric analysis and clinical follow up of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. J Urol 1995; 154: 347–351
   PubMedGoogle Scholar
• Goeman L, Joniau S, Ponette D, Van der Aa F, Roskams T, Oyen R, Van Poppel H. Is low-grade prostatic intraepithelial neoplasia a risk factor for cancer?. Prostate Cancer Prostatic Dis 2003; 6: 305–310
   PubMedGoogle Scholar
• Weinstein M H, Epstein J I. Significance of high-grade prostatic intraepithelial neoplasia on needle biopsy. Hum Pathol 1993; 24: 624–629
   PubMed Web of Science ®Google Scholar
• Sinha A A, Quast B J, Reddy P K, Lall V, Wilson M J, Qian J, Bostwick D G. Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer. Exp Mol Pathol 2004; 77: 153–159
   PubMedGoogle Scholar
• Bostwick D G, Amin M B, Dundore P, Marsh W, Schultz D S. Architectural patterns of high-grade prostatic intraepithelial neoplasia. Hum Pathol 1993; 24: 298–310
   PubMed Web of Science ®Google Scholar
• McNeal J E, Bostwick D G. Intraductal dysplasia: a pre-malignant lesion of the prostate. Hum Pathol 1986; 17: 64–71
   PubMed Web of Science ®Google Scholar
• Cohen R J, McNeal J E, Baillie T. Patterns of differentiation and proliferation in intraductal carcinoma of the prostate: significance for cancer progression. Prostate 2000; 43: 11–19
   PubMedGoogle Scholar
• Dovey Z, Corbishley C M, Kirby R S. Prostatic intraepithelial neoplasia: a risk factor for prostate cancer. Can J Urol 2005; 12: 49–52
   PubMedGoogle Scholar
• Lefkowitz G K, Taneja S S, Brown J, Melamed J, Lepor H. Follow-up interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. J Urol 2002; 168: 1415–1418
   PubMed Web of Science ®Google Scholar
• Gaudin P B, Sesterhenn I A, Wojno K J, Mostofi F K, Epstein J I. Incidence and clinical significance of high-grade prostatic intraepithelial neoplasia in TURP specimens. Urology 1997; 49: 558–563
   PubMed Web of Science ®Google Scholar
• Pacelli A, Bostwick D G. Clinical significance of high-grade prostatic intraepithelial neoplasia in transurethral resection specimens. Urology 1997; 50: 335–359
   Google Scholar
• Ronnett B M, Carmichael M J, Carter H B, Epstein J I. Does high-grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels?. J Urol 1993; 150: 386–389
   PubMed Web of Science ®Google Scholar
• Alexander E E, Qian J, Wollan P C, Myers R P, Bostwick D G. Prostatic intraepithelial neoplasia does not appear to raise serum prostate-specific antigen concentrations. Urology 1996; 47: 693–698
   PubMed Web of Science ®Google Scholar
• Darson M F, Pacelli A, Roche P, Rittenhouse H G, Wolfert R L, Saeid M S, Young C Y, Klee G G, Tindall D J, Bostwick D G. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 1999; 53: 939–944
   PubMed Web of Science ®Google Scholar
• Rubin M A, Zhou M, Dhanasekaran S M, Varambally S, Barrette T R, Snada M G, Pienta K J, Ghosh D, Chinnaiyan A M. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002; 287: 1662–1670
   PubMed Web of Science ®Google Scholar
• Coogan C, Bostwick D, Bloom K, Gould V. Glycoprotein A-80 in the human prostate: immunolocalization in prostatic intraepithelial neoplasia, carcinoma, radiation failure, and after neoadjuvant hormonal therapy. Urology 2003; 61: 248–252
   PubMedGoogle Scholar
• Shin S S, Gould V E, Gould J E, Warren W H, Gould K A, Yaremko M L, Manderino G L, Rittenhouse H G, Tomita J T, Jansson D S. Expression of a new mucin-type glycoprotein in select epithelial dysplasias and neoplasms detected immunocytochemically with Mab A-80. APMIS 1989; 97: 1053–1067
   PubMedGoogle Scholar
• Langer J E, Rovner E S, Coleman B G, Yin D, Arger P H, Malkowicz S B, Nisenbaum H L, Rowling S E, Tomaszewski J E, Wein A J, Jacobs J E. Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy. J Urol 1996; 155: 228–231
   PubMed Web of Science ®Google Scholar
• Chan T Y, Epstein J I. Follow-up of atypical prostate needle biopsies suspicious for cancer. Urology 1999; 53: 351–355
   PubMed Web of Science ®Google Scholar
• O'Dowd G J, Miller M G, Orozco R, Veltri R W. Analysis of repeated biopsy results within 1 year after noncancer diagnosis. Urology 2000; 55: 553–559
   PubMed Web of Science ®Google Scholar
• Ellis W J, Brawer M K. Repeat biopsy: who needs it?. J Urol 1995; 153: 1496–1498
   PubMed Web of Science ®Google Scholar
• Kronz J D, Allan C H, Shaikh A A, Epstein J I. Predicting cancer following a diagnosis of high grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol 2001; 25: 1079–1085
   PubMed Web of Science ®Google Scholar
• Shepherd D, Keetch D W, Humphrey P A, Smith D S, Stahl D. Repeat biopsy strategy in men with isolated prostatic intraepithelial neoplasia on prostate needle biopsy. J Urol 1996; 156: 460–463
   PubMedGoogle Scholar
• Sporn M B. Prevention of cancer in the next millennium: report of the chemoprevention working group to the American Association for Cancer Research. Cancer Res 1999; 59: 4743–4758
   PubMedGoogle Scholar
• O'Shaughnessy J A, Kelloff G J, Gordon G B, Dannenberg A J, Hong W K, Fabian C J, Sigman C C, Bertagnolli M M, Stratton S P, Lam S, Nelson W G, Meyskens F L, Alberts D S, Follen M, Rustgi A K, Papadimitrakopoulou V, Scardino P T, Gazdar A F, Wattenberg L W, Sporn M B, Sakr W A, Lippman S M, Von Hoff D D. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002; 8: 314–346
   PubMed Web of Science ®Google Scholar
• Montironi R, Mazzuccelli R, Marshall J R, Bartels P H. Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents. J Clin Pathol 1999; 52: 793–803
   PubMed Web of Science ®Google Scholar
• Montironi R, Magi-Galluzzi C, Muzzonigro G, Prete E, Polito M, Fabris G. Effects of combination endocrine therapy on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. J Clin Pathol 1994; 47: 906–913
   PubMed Web of Science ®Google Scholar
• Bostwick D G, Qian J. Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia. Urology, 582: S91–S93, Suppl 1
   Google Scholar
• van d er, Kwast T H, Labrie F, Tetu B. Prostatic intraepithelial neoplasia and endocrine manipulation. Eur Urol 1999; 35: 508–510
   PubMedGoogle Scholar
• Lieberman R, Bermejo C, Akaza H, Greenwald P, Fair W, Thompson I. Progress in prostate cancer chemoprevention: modulators of promotion and progression. Urology 2001; 58: 835–842
   PubMedGoogle Scholar
• Yamauchi A, Kawai K, Tsukamoto S, Ideyama Y, Shirai T, Akaza H. Persistence of prostatic intraepithelial neoplasia after effective chemoprevention of microscopic prostate cancer with antiandrogen in a rat model. J Urol 2006; 175: 348–352
   PubMedGoogle Scholar
• Koivisto P A, Schleutker J, Helin H, Ehren-van Eekelen C, Kallioniemi O P, Trapman J. Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia. Clin Cancer Res 1999; 5: 3378–3382
   Google Scholar
• Yang X J, Lecksell K, Short K, Gottesman J, Peterson L, Bannow J, Schellhammer P F, Fitch W P, Hodge G B, Parra R, Rouse S, Waldstreicher J, Epstein J I. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 1999; 53: 696–700
   PubMedGoogle Scholar
• Cote R J, Skinner E C, Salem C E, Mertes S J, Stanczyk F Z, Henderson B E, Pike M C, Ross R K. The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. Br J Cancer 1998; 78: 413–418
   PubMedGoogle Scholar
• Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006; 66: 1234–1240
   PubMed Web of Science ®Google Scholar
• Raghow S, Hooshdaran M Z, Katiyar S, Steiner M S. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 2002; 62: 1370–1376
   PubMed Web of Science ®Google Scholar
• Montironi R, Santinelli A, Mazzucchelli R. Prostatic intraepithelial neoplasia and prostate cancer. Panminerva Med 2002; 44: 213–220
   PubMedGoogle Scholar
• Davidson D, Bostwick D, Qian J, Wollan P C, Oesterling J E, Rudders R A, Siroky M, Stilmant M. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J Urol 1995; 154: 1295–1299
   PubMed Web of Science ®Google Scholar
• Cheng L, Cheville J C, Pisansky T M, Sebo T J, Slezak J, Bergstralh E J, Neumann R M, Singh R, Pacelli A, Zincke H, Bostwick D G. Prevalence and distribution of prostatic intraepithelial neoplasia in salvage radical prostatectomy specimens after radiation therapy. Am J Surg Pathol 1999; 23: 803–808
   PubMed Web of Science ®Google Scholar
• Banach-Petrosky W, Ouyang X, Gao H, Nader K, Ji Y, Suh N, Di Paola R S, Abate-Shen C. Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice. Clin Cancer Res 2006; 12: 5895–5901
   PubMed Web of Science ®Google Scholar
• Kelloff G J, Lieberman R, Brawer M K, Crawford E D, Labrie F, Miller G J, Kelloff G J. Strategies for chemoprevention of prostate cancer. Prostate Cancer Prostatic Dis 1999; 2: S27–S33, Supp1
   PubMed Web of Science ®Google Scholar
• Kopelovich L, Crowell J A, Fay J R. The epigenome as a target for cancer chemoprevention. J Nat Cancer Inst 2003; 95: 1747–1757
   PubMed Web of Science ®Google Scholar
• Marks P, Rifkind R A, Richon V M, Breslow R, Miller T, Kelly W K. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194–202
   PubMed Web of Science ®Google Scholar
• Sandor V, Bakke S, Robey R W, Kang M H, Blagosklonny M V, Bender J, Brooks R, Piekarz R L, Tucker E, Figg W D, Chan K K, Goldspiel B, Fojo A T, Balcerzak S P, Bates S E. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8: 718–728
   PubMed Web of Science ®Google Scholar
• Kang G H, Lee S, Lee H J, Hwang K S. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 2004; 202: 233–240
   PubMed Web of Science ®Google Scholar
• Patra S K, Patra A, Dahiya R. Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun 2001; 287: 705–713
   PubMed Web of Science ®Google Scholar
• Yamanaka M, Watanabe M, Yamada Y, Takagi A, Murata T, Takahashi H, Suzuki H, Ito H, Tsukino H, Katoh T, Sugimura Y, Shiraishi T. Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer 2003; 106: 382–387
   PubMed Web of Science ®Google Scholar
• Tomlins S A, Rhodes D R, Perner S, Dhanasekaran S M, Mehra R, Sun X W, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie J E, Shah R B, Pienta K J, Rubin M A, Chinnaiyan A M. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644–648
   PubMed Web of Science ®Google Scholar
• Epstein J I. What's new in prostate cancer disease assessment in 2006?. Curr Opin Urol 2006; 16: 146–151
   PubMedGoogle Scholar
• Epstein J I, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 2006; 175: 820–834
   PubMed Web of Science ®Google Scholar